Neuromodulation for Apathy in Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled Pilot Study

Prasad R Padala, Eugenia M Boozer, Shelly Y Lensing, Christopher M Parkes, Cassandra R Hunter, Richard A Dennis, Ricardo Caceda, Kalpana P Padala, Prasad R Padala, Eugenia M Boozer, Shelly Y Lensing, Christopher M Parkes, Cassandra R Hunter, Richard A Dennis, Ricardo Caceda, Kalpana P Padala

Abstract

Background: Apathy, a profound loss of motivation, initiation, and goal directed cognition, is a common comorbidity of Alzheimer's disease (AD). The presence of apathy is associated with rapid progression of AD, long-term impairment, disability, and higher mortality. Pharmacological treatments of apathy are limited.

Objective: The primary objective was to evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) for apathy in AD.

Methods: A randomized, double-blind, parallel-arm, sham-controlled pilot study was conducted in subjects with AD and apathy (N = 20). Subjects were randomized to rTMS or sham treatment (5 days/week) for four weeks. Primary outcome, apathy evaluation scale-clinician version (AES-C), and secondary outcome measures, modified-Mini Mental State Examination (3MS), instrumental activities of daily living (IADL), and clinical global impression (CGI), were assessed at baseline and four weeks. Follow-up visits were conducted at 8 and 12 weeks to test the durability of effects of intervention.

Results: Mean age was 77.3 (±7.2) years, 80% were Caucasians and 10% were females. After adjusting for baseline, there was a significantly greater improvement in the AES-C with rTMS compared to sham treatment (-10.1 (-15.9 to -4.3); t (16) = -3.69; p = 0.002) at 4 weeks. There was also significantly greater improvement in 3MS (6.9 (1.7 to 12.0); t (15) = 2.85; p = 0.012), IADL (3.4 (1.0 to 5.9); χ21 = 7.72; p = 0.006), CGI-S (1.4 (0.5 to 2.3), t (16) = 3.29; p = 0.005), and CGI-I (-2.56 (-3.5 to -1.6), t (17) = -5.72; p < 0.001) for rTMS compared to the sham at 4 weeks. The effects of rTMS were durable at 12 weeks.

Conclusion: rTMS may be safely used in subjects with AD and may improve apathy, function, and some aspects of cognition.

Trial registration: ClinicalTrials.gov NCT02190084.

Keywords: Alzheimer’s disease; apathy; behavioral problems in dementia; repetitive transcranial magnetic stimulation.

Conflict of interest statement

Authors’ disclosures available online (https://www.j-alz.com/manuscript-disclosures/20-0640r2).

Figures

Fig. 1
Fig. 1
Screening, Enrollment, and Participation aReason for exclusion: 1-substance abuse, 3-travel, 6-not interested, 4-time, 4-bipolar disorder, 4-did not meet criteria for AD, 3-h/o head trauma, 1-contraindicated medication (bupropion), 1-implants, 1-another study, 2-younger age, 2-h/o stroke, 1-deteriorating caregiver health.

References

    1. GBD 2016 Dementia Collaborators (2019) Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18, 88–106.
    1. Ishii S, Weintraub N, Mervis JR (2009) Apathy: A common psychiatric syndrome in the elderly. J Am Med Dir Assoc 10, 381–393.
    1. Robert P, Onyike CU, Leentjens AF, Dujardin K, Aalten P, Starkstein S, Verhey FR, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorca PM, Thibaut F, Gauthier S, Grossberg G, Vellas B, Byrne J (2009) Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. Eur Psychiatry 24, 98–104.
    1. Holthoff VA, Beuthien-Baumann B, Kalbe E, Lüdecke S, Lenz O, Zündorf G, Spirling S, Schierz K, Winiecki P, Sorbi S, Herholz K (2005) Regional cerebral metabolism in early Alzheimer’s disease with clinically significant apathy or depression. Biol Psychiatry 57, 412–421.
    1. Starkstein SE, Mizrahi R, Capizzano AA, Acion L, Brockman S, Power BD (2009) Neuroimaging correlates of apathy and depression in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci 21, 259–265.
    1. Wongpakaran N, van RR, Wongpakaran T, Clarke D (2007) Selective serotonin reuptake inhibitor use associates with apathy among depressed elderly: A case-control study. Ann Gen Psychiatry 6, 7.
    1. Barnhart WJ, Makela EH, Latocha MJ (2004) SSRI-induced apathy syndrome: A clinical review. J Psychiatr Pract 10, 196–199.
    1. Rog LA, Park LQ, Harvey DJ, Huang CJ, Mackin S, Farias ST (2014) The independent contributions of cognitive impairment and neuropsychiatric symptoms to everyday function in older adults. Clin Neuropsychol 28, 215–236.
    1. Onyike CU, Sheppard JM, Tschanz JT, Norton MC, Green RC, Steinberg M, Welsh-Bohmer KA, Breitner JC, Lyketsos CG (2007) Epidemiology of apathy in older adults: The Cache County Study. Am J Geriatr Psychiatry 15, 365–375.
    1. Clarke DE, Ko JY, Lyketsos C, Rebok GW, Eaton WW (2010) Apathy and cognitive and functional decline in community-dwelling older adults: Results from the Baltimore ECA longitudinal study. Int Psychogeriatr 22, 819–829.
    1. Freels S, Cohen D, Eisdorfer C, Paveza G, Gorelick P, Luchins DJ, Hirschman R, Ashford JW, Levy P, Semla T (1992) Functional status and clinical findings in patients with Alzheimer’s disease. J Gerontol 47, M177–M182.
    1. Okura T, Plassman BL, Steffens DC, Llewellyn DJ, Potter GG, Langa KM (2010) Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: The aging, demographics, and memory study. J Am Geriatr Soc 58, 330–337.
    1. van der Linde RM, Matthews FE, Dening T, Brayne C (2016) Patterns and persistence of behavioural and psychological symptoms in those with cognitive impairment: The importance of apathy. Int J Geriatr Psychiatry 32, 306–315.
    1. Padala PR, Padala KP, Monga V, Ramirez DA, Sullivan DH (2012) Reversal of SSRI-associated apathy syndrome by discontinuation of therapy. Ann Pharmacother 46, e8.
    1. Zhang N, Wei C, Du H, Shi FD, Cheng Y (2015) The effect of memantine on cognitive function and behavioral and psychological symptoms in mild-to-moderate Alzheimer’s disease patients. Dement Geriatr Cogn Disord 40, 85–93.
    1. Cummings JL, Koumaras B, Chen M, Mirski D (2005) Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer’s disease: A 26-week, multicenter, open-label study. Am J Geriatr Pharmacother 3, 137–148.
    1. Herrmann N, Rothenburg LS, Black SE, Ryan M, Liu BA, Busto UE, Lanctôt KL (2008) Methylphenidate for the treatment of apathy in Alzheimer disease: Prediction of response using dextroamphetamine challenge. J Clin Psychopharmacol 28, 296–301.
    1. Padala PR, Burke WJ, Shostrom VK, Bhatia SC, Wengel SP, Potter JF, Petty F (2010) Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 18, 371–374.
    1. Rosenberg PB, Lanctôt KL, Drye LT, Herrmann N, Scherer RW, Bachman DL, Mintzer JE, ADMET Investigators (2013) Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: A randomized, placebo-controlled trial. J Clin Psychiatry 74, 810–816.
    1. Scherer RW, Drye L, Mintzer J, Lanctôt K, Rosenberg P, Herrmann N, Padala PR, Brawman-Mintzer O, Burke W, Craft S, Lerner AJ, Levey A, Porsteinsson A, van Dyck CH, ADMET 2 Research Group (2018) The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): Study protocol for a randomized controlled trial. Trials 19, 46.
    1. Swierkosz-Lenart K, Mall JF, von Gunten A (2019) Interventional psychiatry in the management of behavioural and psychological symptoms of dementia: A qualitative review. Swiss Med Wkly 149, w20140.
    1. George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM (1995) Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6, 1853–1856.
    1. Padala PR, Padala KP, Lensing SY, Jackson AN, Hunter CR, Parkes CM, Dennis RA, Bopp MM, Caceda R, Mennemeier MS, Roberson PK, Sullivan DH (2018) Repetitive transcranial magnetic stimulation for apathy in mild cognitive impairment: A double-blind, randomized, sham-controlled, cross-over pilot study. Psychiatry Res 261, 312–318.
    1. Taylor JL, Hambro BC, Strossman ND, Bhatt P, Hernandez B, Ashford JW, Cheng JJ, Iv M, Adamson MM, Lazzeroni LC, McNerney MW (2019) The effects of repetitive transcranial magnetic stimulation in older adults with mild cognitive impairment: A protocol for a randomized, controlled three-arm trial. BMC Neurol 19, 326.
    1. Jeste DV, Palmer BW, Appelbaum PS, Golshan S, Glorioso D, Dunn LB, Kim K, Meeks T, Kraemer HC (2007) A new brief instrument for assessing decisional capacity for clinical research. Arch Gen Psychiatry 64, 966–974.
    1. Marin RS, Biedrzycki RC, Firinciogullari S (1991) Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 38, 143–162.
    1. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189–198.
    1. Keel JC, Smith MJ, Wassermann EM (2001) A safety screening questionnaire for transcranial magnetic stimulation. Clin Neurophysiol 112, 720.
    1. George MS (2010) Transcranial magnetic stimulation for the treatment of depression. Expert Rev Neurother 10, 1761–1772.
    1. Rossi S, Hallett M, Rossini PM, Pascual-Leone A (2009) Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin Neurophysiol 120, 2008–2039.
    1. Aleman A, Enriquez-Geppert S, Knegtering H, Dlabac-de Lange JJ (2018) Moderate effects of noninvasive brain stimulation of the frontal cortex for improving negative symptoms in schizophrenia: Meta-analysis of controlled trials. Neurosci Biobehav Rev 89, 111–118.
    1. Guercio BJ, Donovan NJ, Munro CE, Aghjayan SL, Wigman SE, Locascio JJ, Amariglio RE, Rentz DM, Johnson KA, Sperling RA, Marshall GA (2015) The Apathy Evaluation Scale: A comparison of subject, informant, and clinician report in cognitively normal elderly and mild cognitive impairment. J Alzheimers Dis 47, 421–432.
    1. Strauss ME, Sperry SD (2002) An informant-based assessment of apathy in Alzheimer disease. Neuropsychiatry Neuropsychol Behav Neurol 15, 176–183.
    1. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J (1994) The Neuropsychiatric Inventory: Comprehensive assessment of psychopathology in dementia. Neurology 44, 2308–2314.
    1. Robert P, Lanctôt KL, Agüera-Ortiz L, Aalten P, Bremond F, Defrancesco M, Hanon C, David R, Dubois B, Dujardin K, Husain M, König A, Levy R, Mantua V, Meulien D, Miller D, Moebius HJ, Rasmussen J, Robert G, Ruthirakuhan M, Stella F, Yesavage J, Zeghari R, Manera V (2018) Is it time to revise the diagnostic criteria for apathy in brain disorders? The 2018 international consensus group. Eur Psychiatry 54, 71–76.
    1. Lanctôt KL, Scherer RW, Li A, Vieira D, Coulibaly H, Rosenberg PB, Herrmann N, Lerner AJ, Padala PR, Brawman-Mintzer O, van Dyck CH, Porsteinsson AP, Craft S, Levey AI, Burke W, Mintzer JE (2020) Measuring apathy in Alzheimer’s disease in the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): A comparison of instruments. Am J Ger Psychiatr 20, 30349–3.
    1. McDowell I, Kristjansson B, Hill GB, Hebert R (1997) Community screening for dementia: The Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin Epidemiol 50, 377–383.
    1. Corrigan JD, Hinkeldey NS (1987) Relationships between parts A and B of the Trail Making Test. J Clin Psychol 43, 402–409.
    1. Starkstein SE, Sabe L, Vázquez S, Di Lorenzo G, Martínez A, Petracca G, Tesón A, Chemerinski E, Leiguarda R (1997) Neuropsychological, psychiatric, and cerebral perfusion correlates of leukoaraiosis in Alzheimer’s disease. J Neurol Neurosurg Psychiatry 63, 66–73.
    1. Royall DR, Mahurin RK, Gray KF (1992) Bedside assessment of executive cognitive impairment: The executive interview. J Am Geriatr Soc 40, 1221–1226.
    1. Lawton MP, Brody EM (1969) Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist 9, 179–186.
    1. Guy W (2016) ECDEU Assessment Manual for Psychopharmacology-Revised. InRockville, MD, U.S. DHEW Publ No ADM 76-338. 70, 218–222.
    1. Zarit SH, Reever KE, Bach-Peterson J (1980) Relatives of the impaired elderly: Correlates of feelings of burden. Gerontologist 20, 649–655.
    1. Padala PR, Padala KP, Lensing SY, Ramirez D, Monga V, Bopp MM, Roberson PK, Dennis RA, Petty F, Sullivan DH, Burke WJ (2018) Methylphenidate for apathy in community-dwelling older veterans with mild Alzheimer’s disease: A double-blind, randomized, placebo-controlled trial. Am J Psychiatry 175, 159–168.
    1. Lanctôt KL, Chau SA, Herrmann N, Drye LT, Rosenberg PB, Scherer RW, Black SE, Vaidya V, Bachman DL, Mintzer JE (2014) Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial. Int Psychogeriatr 26, 239–246.
    1. Howard R, Phillips P, Johnson T, O’Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RB, Jacoby R, Adams J, Griffin M, Gray R (2011) Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 26, 812–817.
    1. Cho SS, Strafella AP (2009) rTMS of the left dorsolateral prefrontal cortex modulates dopamine release in the ipsilateral anterior cingulate cortex and orbitofrontal cortex. PLoS One 4, e6725.
    1. Pogarell O, Koch W, Pöpperl G, Tatsch K, Jakob F, Zwanzger P, Mulert C, Rupprecht R, Möller HJ, Hegerl U, Padberg F (2006) Striatal dopamine release after prefrontal repetitive transcranial magnetic stimulation in major depression: Preliminary results of a dynamic [123I] IBZM SPECT study. J Psychiatr Res 40, 307–314.
    1. Pogarell O, Koch W, Pöpperl G, Tatsch K, Jakob F, Mulert C, Grossheinrich N, Rupprecht R, Möller HJ, Hegerl U, Padberg F (2007) Acute prefrontal rTMS increases striatal dopamine to a similar degree as D-amphetamine. Psychiatry Res 156, 251–255.
    1. Chervyakov AV, Chernyavsky AY, Sinitsyn DO, Piradov MA (2015) Possible mechanisms underlying the therapeutic effects of transcranial magnetic stimulation. Front Hum Neurosci 9, 303.
    1. Li X, Nahas Z, Kozel FA, Anderson B, Bohning DE, George MS (2004) Acute left prefrontal transcranial magnetic stimulation in depressed patients is associated with immediately increased activity in prefrontal cortical as well as subcortical regions. Biol Psychiatry 55, 882–890.
    1. Sasaki N, Hara T, Yamada N, Niimi M, Kakuda W, Abo M (2017) The efficacy of high-frequency repetitive transcranial magnetic stimulation for improving apathy in chronic stroke patients. Eur Neurol 78, 28–32.
    1. Kodama T, Kojima T, Honda Y, Hosokawa T, Tsutsui KI, Watanabe M (2017) Oral administration of methylphenidate (Ritalin) affects dopamine release differentially between the prefrontal cortex and striatum: A microdialysis study in the monkey. J Neurosci 37, 2387–2394.
    1. Arnsten AF, Dudley AG (2005) Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: Relevance to therapeutic effects in attention deficit hyperactivity disorder. Behav Brain Funct 1, 2.
    1. Takada M, Tokuno H, Nambu A, Inase M (1998) Corticostriatal projections from the somatic motor areas of the frontal cortex in the macaque monkey: Segregation versus overlap of input zones from the primary motor cortex, the supplementary motor area, and the premotor cortex. Exp Brain Res 120, 114–128.
    1. Janicak PG, O’Reardon JP, Sampson SM, Husain MM, Lisanby SH, Rado JT, Heart KL, Demitrack MA (2008) Transcranial magnetic stimulation in the treatment of major depressive disorder: A comprehensive summary of safety experience from acute exposure, extended exposure, and during reintroduction treatment. J Clin Psychiatry 69, 222–232.
    1. Lisanby SH, Gutman D, Luber B, Schroeder C, Sackeim HA (2001) Sham TMS: Intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biol Psychiatry 49, 460–463.
    1. Mennemeier M, Triggs W, Chelette K, Woods A, Kimbrell T, Dornhoffer J (2009) Sham transcranial magnetic stimulation using electrical stimulation of the scalp. Brain Stimul 2, 168–173.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe